Why the study?
Does progressive dose-escalation of exenatide reduce dose-limiting nausea and vomiting in subjects with type 2 diabetes?
Population
123 subjects with type 2 diabetes
Comparison
Subcutaneous exenatide starting at 0.02 micro… vs Placebo TID for 35 days, followed by exenatide…
Design
RCT, randomized, triple-blind
Follow-up
38 days
Authors
Loading...
Supports gradual exenatide escalation to reduce GI intolerance in T2D; confirms tolerability without efficacy loss in RCT.
Does progressive dose-escalation of exenatide reduce dose-limiting nausea and vomiting in subjects with type 2 diabetes?
Gradual dose-escalation of exenatide significantly reduces the incidence of dose-limiting nausea and vomiting without compromising its glucoregulatory efficacy in patients with type 2 diabetes.
Fineman et al. (2004) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: